The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Thalassemia Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | CLIMB THAL-111: exagamglogene autotemcel for patients with β-thalassemia
Haydar Frangoul, MD, The Children’s Hospital at TriStar Centennial, Nashville, TN, highlights positive results emerging from the CLIMB THAL-111 trial evaluating exagamglogene autotemcel (exa-cel) for patients with transfusion-dependent β-thalassemia (NCT03655678). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Jazz Pharmaceuticals: Speakers Bureau; Editas Medicine: Consultancy; Vertex Pharmaceuticals: Consultancy, Board of Directors/Advisory Committee; Rocket Pharmaceuticals: Consultancy, Member of DSMB for a study.
